Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1986-2-14
pubmed:abstractText
We have compared the beta-adrenoceptor blocking and antihypertensive effects of chronic once daily treatment with conventional metoprolol 200 mg, two 'long-acting' formulations of metoprolol 200 mg and atenolol 100 mg in a cross-over study in 12 hypertensive patients concurrently receiving diuretic therapy. The peak effects of all compounds were similar, with significant reductions in exercise heart rate and blood pressure. Twenty-four hours after dosing only atenolol treatment was consistently associated with a reduction in both exercise heart rate (P less than 0.001) and blood pressure (P less than 0.02) when compared with placebo. Once daily treatment of hypertension with metoprolol, even in 'long-acting' formulations, cannot be recommended because of waning antihypertensive effect which would be missed at routine clinic attendance. Metoprolol should be prescribed twice daily in hypertension. So-called long-acting formulations do not always confer benefits over conventional dose forms.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-1094802, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-348260, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-361165, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-371902, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-436924, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-465276, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-6119103, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-6412795, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-6805588, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-6841542, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7000243, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7104177, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7138751, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-71400, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7144837, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7272165, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7362713, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-7398733, http://linkedlifedata.com/resource/pubmed/commentcorrection/4074607-838796
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
387-91
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial